In this study, we aimed to explore the utility of chromosomal microarray analysis (CMA) in groups of pregnancies with a priori low risk for detection of submicroscopic chromosome abnormalities, ...

The increased sensitivity of chromosomal microarray (CMA) technology as compared with traditional cytogenetic analysis allows for improved detection of genomic alterations. However, there is potential ...

New York, NY—A large, multi-center clinical trial led by researchers from Columbia University Medical Center (CUMC) shows that a new genetic test resulted in significantly more clinically relevant ...

The Finnish biotechnology company Mobidiag announced today the Prove-it(TM) Bacteria test that sets a world record by being able to detect 50 dangerous bacteria simultaneously - including the ...

NEW YORK – After having cut its teeth on the cannabis, food, and COVID-19 testing markets, PathogenDx is poised to launch a microarray-based test for urinary tract infections later this year. The new ...

SCOTTSDALE, Ariz., /PRNewswire/ -- PathogenDx Inc., the innovative provider of DNA-based pathogen testing technology for the cannabis industry, announced today the release of the first quantitative ...

PathogenDx has announced the release of the first quantitative microarray-based test for cannabis, PDx-Quant™, which can determine whether or not a sample exceeds a state or a federal regulatory ...